Anne Fleur Kortekaas-Rijlaarsdam

45 MPH AND ACADEMIC PERFORMANCE: META-ANALYSIS 2 Author, year N Mean age (SD) Design Titration on academic outcome? Relevant academic measures Academic tasks Mediators and moderators Included in meta-analysis If not: reason and results (Pelham et al., 2001) 68 9.1 (1.8) Within subject design comparing placebo to clinically titrated dosage (avg. dose 25 mg.) No Math accuracy Math number attempted PERMP 1,3,4,6,8,9, 10,11,12,13,14 Yes (Benedetto-Nasho & Tannock, 1999) 14 9.6 (1.0) Within subject design comparing placebo to two fixed doses (10 and 20 mg.) Yes, 10 mg. most effective for math accuracy and productivity Math accuracy Math productivity Math sheet 3,4,5,6,7,8,9,10,11,12,13,14 Yes (Elia, Welsh, Guliotta, & Rapoport, 1993) 33 9.3 (4.8) Within subject design comparing placebo to three fixed doses (25, 40 and 70 mg.) No Math accuracy Reading accuracy Barnell Loft 3,4,5,6,7,8,9,10 Yes (Carlson et al., 1992) 24 9.2 (1.4) Within subject design comparing placebo to two fixed doses (0.3 and 0.6 mg/ kg) Yes, 0.3 mg/ kg most effective for reading and 0.6 mg/kg most effective for math Math accuracy Reading accuracy Reading number attempted Mad Minute, Barnell Loft 1,3,4,6,7,8,9,10,12 Yes, in addition to academic improvements on-task behavior improved with 11.5% with MPH compared to placebo (Balthazor, Wagner, & Pelham, 1991) 19 7.7 (n.a.) Within subject design comparing placebo to one fixed dose (0.3 mg/kg) No Reading accuracy Barnell Loft 3,4,5,6,8,9,10,12 Yes (Barkley, DuPaul, & McMurray, 1991) 40 8.6 (1.3) Within subject design comparing placebo to three fixed doses (5, 10 and 15 mg) Yes, 10 mg. most effective for math accuracy Math accuracy RAS math 3,4,5,8,9,10,11,12 Yes (Cunningham et al., 1991) 30 8.8 (2.6) Within subject design comparing placebo to two fixed doses (0.15 and 0.5 mg/ kg) Yes, 0.5 mg/ kg most effective for math accuracy Math accuracy Math sheet 1,3,4,5,6,8,9,10,12 Yes, in addition to academic improvements on-task behavior improved with 12.0% with MPH compared to placebo Supplementary material Table E2.1 Continued